How do you combine two different cultures to create a global company? Tomio Taki joins Jim Blasingame to discuss how his experiences in Japan during WWII contributed to the global success of his family fashion business.

After 6 months of an upward trend, business conditions and confidence have softened. Sam Norwood joins Jim Blasingame to report the May 2012 Tatum Survey of Business Conditions indicates little economic momentum.

Senior citizens are well represented on election day, but what about lobbying? Daniel Weber joins Jim Blasingame to explain why conservative senior citizens need to support lobbying groups that can offset the AARP's agenda.

Do senior citizens need a conservative lobbying alternative to AARP? Daniel Weber joins Jim Blasingame to discuss why he formed AMAC as a conservative alternative to AARP, and why AARP is not a friend of small business.

What is the SBE Council doing in Washington on behalf of small businesses? Karen Kerrigan joins Jim Blasingame to report on the SBE Council’s efforts in Washington on extending tax cuts and diffusing high energy costs.

The U.S. cannot continue on its present financial trajectory and continue to undermine small businesses. Karen Kerrigan joins Jim Blasingame to report on Europe as an economic forecaster for the U.S. and the dangers of not addressing the national debt.

Small businesses are working hard to improve the Greece’s financial crisis. Karen Kerrigan joins Jim Blasingame to report on the resilience, persistence and optimism of small businesses in Greece.

Should U.S. drug companies benefit from European testing results? Avik Roy joins Jim Blasingame to compare the U.S. and European drug testing systems to bring new drugs to the market, plus the added costs of litigation.

Can FDA approval for new drugs become less onerous? Avik Roy joins Jim Blasingame to report on the high costs of FDA-required clinical trials and the advantages of an accelerated trial program.

The cost of taking a new drug to market is over ten times more today than in 1975. Avik Roy joins Jim Blasingame to report on the cost of complying with current FDA regulations is making new drug development prohibitive.